NALTREXONE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Naltrexone Hydrochloride patents expire, and when can generic versions of Naltrexone Hydrochloride launch?
Naltrexone Hydrochloride is a drug marketed by Accord Hlthcare, Barr, Chartwell, Elite Labs, Fosun Pharma, Specgx Llc, and Sun Pharm. and is included in seven NDAs.
The generic ingredient in NALTREXONE HYDROCHLORIDE is naltrexone hydrochloride. There are nineteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the naltrexone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Naltrexone Hydrochloride
A generic version of NALTREXONE HYDROCHLORIDE was approved as naltrexone hydrochloride by BARR on May 8th, 1998.
Summary for NALTREXONE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 7 |
NDAs: | 7 |
Finished Product Suppliers / Packagers: | 14 |
Raw Ingredient (Bulk) Api Vendors: | 71 |
Clinical Trials: | 468 |
Patent Applications: | 5,180 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NALTREXONE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for NALTREXONE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Inventage Lab., Inc. | Phase 1 |
BioXcel Therapeutics Inc | Phase 1/Phase 2 |
Bicycle Health | Phase 4 |
Pharmacology for NALTREXONE HYDROCHLORIDE
Drug Class | Opioid Antagonist |
Mechanism of Action | Opioid Antagonists |